New versus old guidelines for sarcopenia classification: What is the impact on prevalence and health outcomes?
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Introduction: recently, the European Working Group on Sarcopenia in Older People (EWGSOP) established a new operational definition and cut-off points for sarcopenia. The aim of this study was, therefore, to compare the prevalence of sarcopenia and its associations with different health outcomes using the old (EWGSOP1) and new (EWGSOP2) definitions of sarcopenia in the UK Biobank cohort. Methods: sarcopenia was defined as low grip strength plus low muscle mass. Using both EWGSOP cut-off points, we created specific sarcopenia variables. Prevalence of sarcopenia derived using both EWGSOP definitions was calculated and compared as well as prospective health outcomes including all-cause mortality as well as incidence and mortality from cardiovascular disease (CVD), respiratory disease and chronic obstructive pulmonary disease (COPD). Results: the prevalence of sarcopenia based on the EWGSOP1 and EWGSOP2 classifications were 8.14 and 0.36%, respectively. Sarcopenia defined by EWGSOP1 was associated with a higher risk of respiratory disease and COPD as well as mortality from all-cause, CVD and respiratory diseases. However, only respiratory incidence remained associated with sarcopenia when EWGSOP2 was used (HR: 1.32 [95% CI: 1.05–1.66]). Moreover, although individuals classified as sarcopenic using both classifications had the highest risk of all-cause mortality and respiratory disease, those with sarcopenia based on EWGSOP1 only experienced a more extensive range of poorer health outcomes. Conclusion: in comparison with EWGSOP1, the new classification (EWGSOP2) produced a lower estimate of sarcopenia prevalence and fewer associations with adverse health outcomes. Although these associations were higher, many become non-significant.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afy169 · Cited by 13,818
Sarcopenia in Asia: Consensus Report of the Asian Working Group for Sarcopenia
Chen, L.-K., Liu, L.-K., Woo, J., Assantachai, P., Auyeung, T.-W., Bahyah, K. S., Chou, M.-Y., Chen, L.-Y., Hsu, P.-S., Krairit, O., et al. (2014) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2013.11.025 · Cited by 4,051 · cited 1×
“Different operational definitions have been proposed to defined sarcopenia, most based on the combination of three primary physical capability markers: low muscle mass, low grip strength and slow gait speed [3-7].”
BackgroundFry, A., Littlejohns, T. J., Sudlow, C., Doherty, N., Adamska, L., Sprosen, T., Collins, R., & Allen, N. E. (2017) · American Journal of Epidemiology · doi:10.1093/aje/kwx246 · Cited by 3,979
Cruz-Jentoft, A. J., & Sayer, A. A. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31138-9 · Cited by 3,905
Sarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afz046 · Cited by 3,803
Fielding, R. A., Vellas, B., Evans, W. J., Bhasin, S., Morley, J. E., Newman, A. B., Abellan van Kan, G., Andrieu, S., Bauer, J., Breuille, D., et al. (2011) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2011.01.003 · Cited by 3,256 · cited 1×
“Different operational definitions have been proposed to defined sarcopenia, most based on the combination of three primary physical capability markers: low muscle mass, low grip strength and slow gait speed [3-7].”
BackgroundStudenski, S. A., Peters, K. W., Alley, D. E., Cawthon, P. M., McLean, R. R., Harris, T. B., Ferrucci, L., Guralnik, J. M., Fragala, M. S., Kenny, A. M., et al. (2014) · The Journals of Gerontology: Series A · doi:10.1093/gerona/glu010 · Cited by 2,545 · cited 1×
“Different operational definitions have been proposed to defined sarcopenia, most based on the combination of three primary physical capability markers: low muscle mass, low grip strength and slow gait speed [3-7].”
BackgroundCruz-Jentoft, A. J., Landi, F., Schneider, S. M., Zuniga, C., Arai, H., Boirie, Y., Chen, L.-K., Fielding, R. A., Martin, F. C., Michel, J.-P., et al. (2014) · Age and Ageing · doi:10.1093/ageing/afu115 · Cited by 1,963
The developmental origins of sarcopenia
Sayer, A. A., Syddall, H., Martin, H., Patel, H., Baylis, D., & Cooper, C. (2008) · The Journal of nutrition, health and aging · doi:10.1007/bf02982703 · Cited by 450 · cited 1×
“In this context, and although the development of sarcopenia starts during adult life [15], the prevalence of sarcopenia using the new definition could be higher in an older population.”
BackgroundThe implications of sarcopenia and sarcopenic obesity on cardiometabolic disease
Kim, T. N., & Choi, K. M. (2015) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25077 · Cited by 225 · cited 1×
“outcomes have been widely studied [16-18].”
Cited by
Sarcopenic obesity in ageing: cardiovascular outcomes and mortality
Atkins, J. L., & Wannamathee, S. G. (2020) · British Journal of Nutrition · doi:10.1017/s0007114520002172 · Cited by 187
Factors associated with sarcopenia: A cross-sectional analysis using UK Biobank
Petermann-Rocha, F., Chen, M., Gray, S. R., Ho, F. K., Pell, J. P., & Celis-Morales, C. (2020) · Maturitas · doi:10.1016/j.maturitas.2020.01.004 · Cited by 172
“as having sarcopenia because the new definition has decreased the cut-off points of the physical capability markers [8-10].”
BackgroundSelf-citationWelsh, C. E., Celis-Morales, C. A., Ho, F. K., Brown, R., Mackay, D. F., Lyall, D. M., Anderson, J. J., Pell, J. P., Gill, J. M. R., Sattar, N., et al. (2020) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.12.032 · Cited by 85
Self-citation
Metadata
- Authors
- Petermann-Rocha, F., Chen, M., Gray, S. R., Ho, F. K., Pell, J. P., & Celis-Morales, C.
- Venue
- Age and Ageing
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-11-15
- Volume
- 49
- Issue
- 2
- Pages
- 300-304
- ISSN
- 0002-0729 (ISSN-L)
- 1468-2834
- OpenAlex
- W2971847438
- Cited by
- 53
- References
- 11
- FWCI
- 5.00
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: New versus old guidelines for sarcopenia classification: What is the impact on prevalence and health outcomes? https://app.cochat.ai/papers/10.1093/ageing/afz126
- The paper
- Petermann-Rocha, F., Chen, M., Gray, S. R., Ho, F. K., Pell, J. P., & Celis-Morales, C. (2019). New versus old guidelines for sarcopenia classification: What is the impact on prevalence and health outcomes? Age and Ageing. https://doi.org/10.1093/ageing/afz126
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.